



## **Dorset Clinical Commissioning Group**

Vespasian House  
Barrack Road  
Dorchester  
Dorset  
DT1 1TG

Tel: 01305 368900  
Fax: 01305 368947  
[www.dorsetccg.nhs.uk](http://www.dorsetccg.nhs.uk)

Ref: FOI 108

4 September 2019

Dear Requestor

### **Request made under the Freedom of Information Act 2000**

On 13 August 2019 you sent a request, made under the Freedom of Information Act, relating to emollient flammability. I now provide this information as an attachment.

I trust that this is the information you require and that your request has been fully discharged.

Any information supplied to you is protected by the Copyright, Designs and Patents Act 1988. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other re-use, for example commercial publication and subscription charge, would require the permission of the copyright holder.

Please note that, under the Re-use of Public Sector Information Regulations, if you wish to publish or otherwise use this information besides for your own means, you will need to seek our permission to do so.

If you are unhappy with this response, you are entitled to request an internal review of our decision, handled where possible by a member of staff not directly involved in the initial decision. If you wish to request such a review, please write direct to the Data Protection Officer, NHS Dorset, Ground Floor, West Wing, Vespasian House, Barrack Road, Dorchester DT1 1TG. We aim to deal with requests for internal review within three weeks of receipt, although where the issues involved are very complicated this period may be extended up to a total of six weeks.

If you have queries about this response, please do not hesitate to contact me quoting the above reference number.

Yours sincerely

***Signature Removed***

**Paddy Baker**  
Data Protection Officer  
NHS Dorset Clinical Commissioning Group

**Reference: FOI 108**

**Q1:**

Has this information provided by the MHRA been implemented across your CCG to advise healthcare professionals?

**Response:**

Yes, the information provided by the MHRA has been implemented across the CCG.

**Q2:**

How has this been implemented? Please also provide details of any future intentions.

**Response:**

Discussed with specialist clinicians and GPs, information provided on the local formulary, information provided within the prescribing newsletter to GPs.

**Q3:**

Has this information provided by the MHRA been implemented across your CCG to advise the public on how to use emollient skin products safely?

**Response:**

Yes, the information provided by the MHRA been implemented across the CCG.

**Q4:**

How has this been implemented? Please also provide details of any future intentions.

**Response:**

Patient information leaflets are available on the formulary to provide during consultation. The Formulary is also available to patients and community pharmacies if they wish to access the leaflet from there.